Graham C. Parry

Executive Vice President, Translational Sciences
Vega Therapeutics, Inc.
South San Francisco, California, United States

Presentation(s):

• OC 73.3 - VGA039, a Protein S-targeting monoclonal antibody, demonstrates in a Phase Ia healthy volunteer trial the potential of subcutaneous weekly or less frequent prophylactic dosing for bleeding disorders

  Wednesday, June 26, 2024
  10:45 – 11:00 ICT